Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Novartis reported an impressive 11% increase in sales in constant currency, accompanied by a 21% rise in core operating income for Q2 2025. This growth underscores the company’s strong financial ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

This pricing shock immediately exposed pharma’s second crisis: R&D costs that continue to climb, now between $0.8 and $2.8 ...

Mesoblast Ltd (ASX: MSB) shares could still be relatively cheap despite doubling in value according to one leading ...

The Federal Circuit won’t block the launch of MSN Pharmaceuticals Inc.'s copy of the lucrative heart-failure drug Entresto while Novartis Pharmaceuticals Corp. appeals its loss in a patent ...

27 May 2025 Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic ...

Trump diagnosed with chronic venous insufficiency; BMS, Pfizer to sell Eliquis at a discount; Ireland exporting more pharma products ahead of potential tariff. Get to know each of these companies by ...